A targeted treatment with off-target risks

David A. Fruman () and Susan O'Brien
Additional contact information
David A. Fruman: University of California, Irvine, Irvine, California 92697, USA.
Susan O'Brien: Susan O'Brien is at the Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange, California 92868, USA.

Nature, 2017, vol. 542, issue 7642, 424-425

Abstract: It emerges that blood-cancer-targeting drugs that block a tumour-survival pathway also activate a mutation-causing enzyme in mice and in human cells. This might have implications for the clinical use of these drugs. See Letter p.489

Date: 2017
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/nature21504 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:542:y:2017:i:7642:d:10.1038_nature21504

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/nature21504

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().